Discussion
The ALS Association has awarded Mitochon Pharmaceuticals a $1 million grant to support a Phase 2 clinical trial testing the company’s experimental therapy MP-101 in people with amyotrophic lateral sclerosis (ALS). The study is still in the planning stages and is expected to kick off next year.